乳腺癌患者放疗后血清IL-6与可溶性IL-6受体含量增加并与免疫细胞比例相关

Increased serum IL-6 and soluble IL-6 receptor in breast cancer patients after radiotherapy are correlated with proportions of immune cells

目的探讨乳腺癌患者血清白细胞介素6(IL-6)与可溶性白细胞介素6受体(sIL-6R)水平对放疗后免疫功能的评估价值。方法随机选取术后放疗的55例乳腺癌患者为治疗组、经体检合格的55例正常健康成人为对照组,采用ELISA检测对照组及治疗组患者放疗前后血清IL-6与sIL-6R含量,并以流式细胞术检测治疗组患者放疗前后外周血CD45^+CD19^+B淋巴细胞、CD45^+CD3^+CD4^+T淋巴细胞、CD45^+CD3^+CD8^+T淋巴细胞及CD45^+CD16^+CD56^+自然杀伤(NK)细胞,比较淋巴细胞亚群与IL-6、sIL-6R含量的相关性。结果治疗组患者放疗后血清IL-6与sIL-6R含量显著高于放疗前及对照组,且Ⅲ期、Ⅳ期乳腺癌患者IL-6、sIL-6R含量明显升高。治疗组患者放疗后总T淋巴细胞、NK细胞比例明显降低,B淋巴细胞比例显著升高,且IL-6、sIL-6R含量与NK细胞比例呈正相关,与B淋巴细胞比例负相关。结论乳腺癌患者血清中IL-6与sIL-6R水平可作为乳腺癌病程评估和放疗后免疫功能的参考。

Objective To investigate the value of serum interleukin-6(IL-6) and soluble interleukin-6 receptor(sIL-6R) levels of breast cancer patients in evaluating immune function after radiotherapy. Methods We randomly selected 55 cases of breast cancer patients who had received radiotherapy as an observation group, and 55 cases of normal healthy adults as a control group. ELISA was used to detect serum IL-6 and sIL-6R levels. Flow cytometry was used to detect CD45^+CD19^+ B lymphocytes, CD45^+CD3^+CD4^+ T lymphocytes, CD45^+CD3^+CD8^+ T lymphocytes and CD45^+CD16^+CD56^+ NK cells in peripheral blood. The correlation of lymphocyte subsets with IL-6 or sIL-6R levels was analyzed. Results Serum IL-6 and sIL-6R levels of the observation group patients after radiotherapy were significantly higher than those before radiotherapy and in the control group, and the IL-6 and sIL-6R levels of patients of Ⅲ or Ⅳ stage breast cancer increased significantly. Flow cytometry showed that the ratios of total T lymphocytes and NK cells in the observation group after radiotherapy were significantly reduced, while the ratio of B lymphocytes was significantly elevated. In addition, the levels of IL-6 and sIL-6R were positively correlated with the ratio of NK cells and negatively correlated with the ratio of B lymphocytes. ConclusionSerum IL-6 and sIL-6R levels in patients with breast cancer can be used as references for assessing the course of breast cancer and immune function after radiotherapy.